by Elena Iemma | Feb 23, 2024 | News
If you missed the posters that we presented at AAPS NBC 2024, don’t worry! Click each poster below to enlarge it or download. Have questions or interested in discussing these studies more? Send us a message here. An “I” (Immunogenicity Risk...
by Elena Iemma | Dec 20, 2023 | News
PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
by Elena Iemma | Nov 20, 2023 | News
EpiVax CEO Annie De Groot was one of three plenary session speakers at a recent international forum on vaccines organized by Joon Rhee. Her topic was ‘Better, Safer, and Personalized Vaccines will Result from Human + Artificial Intelligence’. Other speakers...
by Elena Iemma | Aug 10, 2023 | News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...
by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
by Elena Iemma | May 16, 2023 | News
EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998 EpiVax Founded by Dr....
